CellCentric raises a £160m Series D led by Venrock Healthcare Capital Partners for oral drug designed to treat multiple myeloma and other cancers

CellCentric develops inobrodib, an oral drug designed to treat multiple myeloma and other cancers. The treatment is intended to provide a new option for patients, including those who have already undergone multiple lines of therapy.